Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional rituximab for relapsed or refractory CD20-positive indolent conjunctival lymphoma
2011-004908-37Phase 2Completed
- Sponsor
- Fondazione Centro San Raffaele
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in conjunctival lymphoma, non-Hodgkin lymphoma (NHL) and low-grade B-cell lymphoma (2 arms), sponsored by Fondazione Centro San Raffaele. Primary endpoint: Safety of intralesional rituximab. Started Dec 2011; status: completed.
02
Drugs
rituximab
03
Conditions
conjunctival lymphomanon-Hodgkin lymphoma (NHL)low-grade B-cell lymphoma
Beyond the preview
Go deeper on 2011-004908-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004908-37.